GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artgen Biotech PJSC (MIC:ABIO) » Definitions » ROE %

Artgen Biotech PJSC (MIC:ABIO) ROE % : 17.65% (As of Jun. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Artgen Biotech PJSC ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Artgen Biotech PJSC's annualized net income for the quarter that ended in Jun. 2023 was ₽64 Mil. Artgen Biotech PJSC's average Total Stockholders Equity over the quarter that ended in Jun. 2023 was ₽361 Mil. Therefore, Artgen Biotech PJSC's annualized ROE % for the quarter that ended in Jun. 2023 was 17.65%.

The historical rank and industry rank for Artgen Biotech PJSC's ROE % or its related term are showing as below:

MIC:ABIO' s ROE % Range Over the Past 10 Years
Min: -100.08   Med: 0.23   Max: 122.66
Current: 15.91

During the past 13 years, Artgen Biotech PJSC's highest ROE % was 122.66%. The lowest was -100.08%. And the median was 0.23%.

MIC:ABIO's ROE % is ranked better than
93.31% of 1360 companies
in the Biotechnology industry
Industry Median: -43.445 vs MIC:ABIO: 15.91

Artgen Biotech PJSC ROE % Historical Data

The historical data trend for Artgen Biotech PJSC's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artgen Biotech PJSC ROE % Chart

Artgen Biotech PJSC Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -87.44 122.66 47.76 5.42 16.02

Artgen Biotech PJSC Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.89 -7.06 19.57 13.67 17.65

Competitive Comparison of Artgen Biotech PJSC's ROE %

For the Biotechnology subindustry, Artgen Biotech PJSC's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Artgen Biotech PJSC's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artgen Biotech PJSC's ROE % distribution charts can be found below:

* The bar in red indicates where Artgen Biotech PJSC's ROE % falls into.



Artgen Biotech PJSC ROE % Calculation

Artgen Biotech PJSC's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=46.118/( (234.779+341.039)/ 2 )
=46.118/287.909
=16.02 %

Artgen Biotech PJSC's annualized ROE % for the quarter that ended in Jun. 2023 is calculated as

ROE %=Net Income (Q: Jun. 2023 )/( (Total Stockholders Equity (Q: Dec. 2022 )+Total Stockholders Equity (Q: Jun. 2023 ))/ count )
=63.756/( (341.039+381.318)/ 2 )
=63.756/361.1785
=17.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2023) net income data. ROE % is displayed in the 30-year financial page.


Artgen Biotech PJSC  (MIC:ABIO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=63.756/361.1785
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(63.756 / 1242.23)*(1242.23 / 2200.04)*(2200.04 / 361.1785)
=Net Margin %*Asset Turnover*Equity Multiplier
=5.13 %*0.5646*6.0913
=ROA %*Equity Multiplier
=2.9 %*6.0913
=17.65 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=63.756/361.1785
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (63.756 / 86.874) * (86.874 / 157.192) * (157.192 / 1242.23) * (1242.23 / 2200.04) * (2200.04 / 361.1785)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.7339 * 0.5527 * 12.65 % * 0.5646 * 6.0913
=17.65 %

Note: The net income data used here is two times the semi-annual (Jun. 2023) net income data. The Revenue data used here is two times the semi-annual (Jun. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Artgen Biotech PJSC ROE % Related Terms

Thank you for viewing the detailed overview of Artgen Biotech PJSC's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Artgen Biotech PJSC (MIC:ABIO) Business Description

Traded in Other Exchanges
N/A
Address
Prospect of the 60th Anniversary, Moscow, RUS, 117036
Artgen Biotech PJSC formerly Human Stem Cells Institute PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.

Artgen Biotech PJSC (MIC:ABIO) Headlines

From GuruFocus

Jacob Ma-Weaver Joins ARCA biopharma Board of Directors

By GuruFocusNews GuruFocusNews 07-01-2022

Jacob Ma-Weaver Joins ARCA biopharma Board of Directors

By PurpleRose PurpleRose 07-11-2022

ARCA biopharma Announces First Quarter 2023 Financial Results

By sperokesalga sperokesalga 04-24-2023

James Flynn Joins ARCA biopharma Board of Directors

By Value_Insider Value_Insider 12-19-2022

ARCA biopharma Establishes Special Committee of the Board of Directors

By GuruFocusNews GuruFocusNews 04-18-2022